Sign in
Not yet taking people in SwedenPhase 2

Tests tadalafil to help sexual function after rectal cancer treatment

Tests tadalafil in men and women after treatment for rectal cancer.

Key facts

Who runs it
Karolinska Institutet
Where
Gothenburg, Malmo, and Solna, SwedenSee the 3 sites
Registry title
Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized placebo-controlled study with tadalafil
Status
Not yet recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
7 Dec 2020
Planned end
30 Jun 2026
Type of study
Interventional
Record updated
27 September 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men and women with stage I-III rectal cancer who plan to have abdominal surgery to remove it and were sexually active before the diagnosis.

Age
Over 18 years
Sex
Men and women
Disease stage
Rectal cancer stage I-III, with surgery by the abdominal route planned.
Earlier treatment
Must not have had pelvic radiation. Must not be using anti-androgens or androgens.

Main reasons for not taking part

  • Cancer that has spread (metastases)
  • History of cancer of the urinary or genital organs
  • Reasons why tadalafil (a PDE5-inhibitor) cannot be used
  • ECOG performance score above 1
  • Serious mental disorder or medical condition, such as anaemia, liver or kidney failure, heart disease or diabetes

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Men and women with rectal cancer stage I-III after clinical and radiologic staging, intention to transabdominal resection of rectal cancer
  • Patient reported sexual activity before diagnosis or symptoms of rectal cancer according to FSFI-6 and IIEF-5
  • Age over 18 years
  • Fluent in oral and written Swedish language
  • Females must not be lactating or pregnant at baseline documented by pregnancy test
  • Given written informed consent

Who cannot take part

  • Concomitant use of anti-androgens or androgens
  • Contraindications to the use of tadalafil (PDE5-inhibitor)
  • Ongoing drug or alcohol abuse dependence
  • Has a condition or has received medical treatment that, in the judgement of the investigator, precluded successful participation in the study
  • Evidence of systemic disease (metastases)
  • History or evidence of urogenital malignancy
  • History of pelvic radiation
  • Serious co-existing mental disorder or medical condition e.g. anaemia, liver or renal failure, cardiovascular disease or diabetes
  • Impaired performance status (Eastern Cooperative Oncology Group (ECOG) performance score above 1

Where in Sweden

  • Sahlgrenska University Hospital-Vaestra GoetalandsregionenGothenburg, SwedenNot yet recruiting
  • Region Skane Skanes UniversitetssjukhusMalmo, SwedenNot yet recruiting
  • Karolinska University HospitalSolna, SwedenNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the effect of prophylactic intake of 5 mg tadalafil on sexual/erectile function in women and men within a standardized rehabilitation program after treatment for rectal cancer.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized controlled study with tadalafil compared to standard care
Plain-language title
Tests tadalafil to help sexual function after rectal cancer treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
27 September 2024